Characteristics of Individuals with Migraine Who Are Eligible for Novel CGRP Monoclonal Antibodies: Results of the OVERCOME Study
In this medfyle
Expert commentary by Carrie Dougherty, MD, FAHS
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:
Richard B. Lipton, MD
Professor and Vice Chair of Neurology
Albert Einstein College of Medicine
Bronx, New York
The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Carrie Dougherty, MD, FAHS
Associate Professor of Neurology
Fellowship Program Director, Headache Medicine
Assistant Residency Program Director, Neurology
MedStar Georgetown University Hospital
About the Expert
Carrie Dougherty, MD, FAHS
Associate Professor of Neurology
Fellowship Program Director, Headache Medicine
Assistant Residency Program Director, Neurology
MedStar Georgetown University Hospital
Carrie Dougherty, MD, is associate professor of neurology and program director of the headache medicine fellowship at MedStar Georgetown University Hospital in Washington, DC. She is a fellow of the American Headache Society and serves as a member of the Guidelines committee and the Scottsdale Headache Symposium Planning committee. She is secretary of the Southern Headache Society and the Alliance for Headache
Disorders Advocacy.
References
1. American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments Into Clinical Practice. Headache 2019;59:1-18.
2. Silberstein SD, et al. Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-1345.
3. Lipton RB, et al. Cutaneous Allodynia in the Migraine Population. Annals of Neurology 2008;63:148-158.
4. Lipton RB, et al. Validity and Reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia 2009;29:751-759.
5. Stewart WF, et al. Development and Testing of the Migraine Disability Assessment (MIDAS) Questionnaire to Assess Headache-Related Disability. Neurology 2001;56(6 Supp 1):S20-28.
